Every one of those 1 sits in a single category, pharma. Fosun Pharma is most often covered alongside Gland Pharma, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Fosun Pharma
Every one of those 1 sits in a single category, pharma. Fosun Pharma is most often covered alongside Gland Pharma, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Biotech story that mention Fosun Pharma, all published on March 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Fosun Pharma. Shared-story counts are live from our verified record — not editorial picks.
Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.